1.Prognostic Significance of Ki-67 Expression in Patients Undergoing Surgical Resection for Gastrointestinal Stromal Tumor.
Seong Yeon JEONG ; Won Wo PARK ; You Sun KIM ; Young Il PARK ; Seung Hyup KIM ; Won Jae YOON ; Jeong Seop MOON ; Byung Mo LEE ; Seong Woo HONG ; Yun Kyung KANG
The Korean Journal of Gastroenterology 2014;64(2):87-92
BACKGROUND/AIMS: Assessment of malignant potential in gastrointestinal stromal tumor (GIST) is still problematic. The maximum tumor diameter and the mitotic index are generally used as an index of malignancy of GISTs. The Ki-67 labeling index has recently been used as an index of cell growth. The aim of this study was to investigate the prognostic value of Ki-67 in GIST. METHODS: We retrospectively reviewed the medical records of 32 patients with GIST who underwent surgical resection at Inje University Seoul Paik Hospital. We analyzed their Ki-67 expression, histologic finding, and prognosis. RESULTS: According to the tumor size and mitotic count, 4 patients were classified as very low risk, 9 patients as low risk, 14 patients as intermediate risk and 5 patients as high risk. The average Ki-67 index was 5.56+/-4.48%. The median follow-up duration was 35.72+/-29.04 months, and local/distant recurrences were observed in 6 (18.7%) patients. The overall cumulative disease free survival rates in patients with Ki-67 index < or =5% at 1 year, 2 years, and 5 years were 100%, 100%, and 86%, respectively. The overall cumulative disease free survival rates in patients with Ki-67 index >5% were at 1 year, 2 years, and 5 years were 82.1%, 70.3%, and 46.9%, respectively. There was significant relationship between elevated Ki-67 and disease free survival rate (p=0.007). CONCLUSIONS: Our study suggests that Ki-67 index >5% confers a higher risk of relapse in patients with GIST. Future work should focus on standardization of Ki-67 assessment and specification of its role in making treatment decisions.
Adult
;
Aged
;
Disease-Free Survival
;
Female
;
Gastrointestinal Neoplasms/*diagnosis/mortality/pathology
;
Gastrointestinal Stromal Tumors/*diagnosis/mortality/pathology
;
Humans
;
Immunohistochemistry
;
Kaplan-Meier Estimate
;
Ki-67 Antigen/*metabolism
;
Linear Models
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local
;
Prognosis
;
Retrospective Studies
2.Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis.
Xiao-Ming DU ; Liu-Hua WANG ; Xiao-Wen CHEN ; Yi-Xiao LI ; Yu-Cong LI ; Yu-Wen CAO
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(3):305-312
The aim of the present study was to accurately evaluate the association of Sox2 expression with the survival of patients with digestive tract cancers. Relevant literatures were identified by comprehensively searching databases including the Pubmed, Embase, CBMdisc, and Wanfang (up to October 2014). A meta-analysis was performed to clarify the association between Sox2 expression and overall survival or clinicopathological parameters of patients with digestive tract cancers (esophageal, gastric, and colorectal cancers). The results showed a significant association between high Sox2 expression and poor overall survival in patients with digestive tract carcinomas (HR=1.55, 95% CI=1.04-2.31), especially for patients with esophageal cancer (HR=2.04, 95%CI=1.30-3.22), colorectal cancer (HR=1.40, 95% CI=1.04-1.89), and digestive tract adenocarcinoma (HR=1.80, 95% CI=1.12-2.89), for Europeans (HR=1.98, 95% CI=1.44-2.71) or patients who did not receive neoadjuvant treatment (HR=1.73, 95% CI=1.10-2.72). Furthermore, Sox2 over-expression was highly correlated with vascular invasion (OR=1.86, 95% CI=1.25-2.77) and poor differentiation (OR=1.88, 95% CI=1.14-3.08), especially in esophageal and colorectal cancers. In conclusion, Sox2 expression may serve as a novel prognostic factor for patients with digestive tract cancers. Over-expression of Sox2 that is correlated with vascular invasion and poor differentiation suggests poor outcomes of patients with digestive tract cancers.
Antineoplastic Agents
;
therapeutic use
;
Biomarkers, Tumor
;
genetics
;
metabolism
;
Colorectal Neoplasms
;
diagnosis
;
drug therapy
;
mortality
;
pathology
;
Esophageal Neoplasms
;
diagnosis
;
drug therapy
;
mortality
;
pathology
;
Gastrointestinal Tract
;
metabolism
;
pathology
;
Gene Expression
;
Humans
;
Neoadjuvant Therapy
;
methods
;
Neoplasm Grading
;
Neoplasms, Vascular Tissue
;
diagnosis
;
drug therapy
;
mortality
;
secondary
;
Prognosis
;
SOXB1 Transcription Factors
;
genetics
;
metabolism
;
Stomach Neoplasms
;
diagnosis
;
drug therapy
;
mortality
;
pathology
;
Survival Analysis
3.Clinical and prognostic analysis of 101 cases of primary gastrointestinal non-Hodgkin's lymphoma.
Li-Na SONG ; Xi-Nan CEN ; Jin-Ping OU ; Ze-Yin LIANG ; Zhi-Xiang QIU ; Wen-Sheng WANG ; Wei-Lin XU ; Yuan LI ; Mang-Ju WANG ; Yu-Jun DONG ; Yue YIN ; Yu-Hua SUN ; Wei LIU ; Qian WANG ; Li-Hong WANG ; Ying WANG ; Han-Yun REN
Journal of Experimental Hematology 2013;21(2):387-391
This study was purposed to analyze the clinical characteristics and prognostic factors in patients with primary gastrointestinal non-Hodgkin's lymphoma (PGI-NHL). The pathological data of 101 PGI-NHL patients admitted in our hospital in the past 15 years were analyzed retrospectively. The results showed that 101 patients with PGI-NHL accounted for 14.49% of NHL in the same period, there were 64 males, 37 females, the range of ages was from 18 to 87 years old, median age was 61 years old; in disease distribution, the stomach PGI-NHL accounted for 58.42%, intestine PGI-NHL accounted for 39.60%, multiple GI involvements (MGI) accounted for 1.98%; in pathological type, diffuse large B cell lymphoma (DLBCL) accounted for 66.34%, mucosa-associated lymphoid tissue (MALT) lymphoma accounted for 17.82%, mantle cell lymphoma (MCL) accounted for 3.96%, enteropathy-associated T cell lymphoma (EATL) accounted for 7.92%, extra-nodal nasal type NK/T cell lymphoma accounted for 1.98%, follicular lymphoma (FL) accounted for 0.99%, small lymphocyte lymphoma (SLL) accounted for 0.99%. Eighty-nine out of 101 patients were followed up (49 cases live, 40 cases dead), data of the 12 patients were lost; the median survival time was 29 months (1 - 173). The three-year OS and five-year OS were 58.4% and 52.6% respectively. Univariate analysis revealed that the factors affecting OS included sex (P = 0.004), lesion site (P = 0.002), tumor size (P = 0.011), clinical Lugano staging for gastrointestinal non-Hodgkin's lymphoma (P = 0.003), IPI score (P = 0.000), pathological cell phenotype (P = 0.001), and pathological type (P = 0.006), their differences were statistically significant (P < 0.05). Multivariate Cox regression analysis indicated that clinical Lugano staging for gastrointestinal non-Hodgkin's lymphoma, IPI score, pathological type were independent prognostic risk factors affecting OS. It is concluded that clinical Lugano staging for gastrointestinal non-Hodgkin's lymphoma, IPI score and pathological type are independent risk factors affecting OS.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Female
;
Gastrointestinal Neoplasms
;
diagnosis
;
mortality
;
pathology
;
Humans
;
Lymphoma, Non-Hodgkin
;
diagnosis
;
mortality
;
pathology
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Prognosis
;
Survival Rate
;
Young Adult
4.Clinicopathological characteristics and prognostic analysis of 92 cases with primary gastrointestinal diffuse large B-cell lymphoma.
Jia FENG ; Wei WAN ; Wenli WAN ; Jing WANG ; Hongmei JING ; Jijun WANG ; Wei ZHAO ; Yan LIU ; Xiaoyan KE
Chinese Journal of Hematology 2014;35(4):288-294
OBJECTIVETo analyze the clinical and pathological features, molecular biological markers and prognosis of primary gastrointestinal diffuse large B-cell lymphoma (DLBCL).
METHODSA retrospective study was conducted in 92 cases of primary gastrointestinal DLBCL. The data of clinical characteristics, pathological and immunohistochemical features were analyzed. The relationship between different factors at diagnosis and prognosis were studied.
RESULTSOf the 92 patients, the male-female ratio was 1.56:1 with a median age of 59(7-89) years. The most frequently involved site was stomach (50.0%), followed by small intestine (15.2%), colon (12.0%), ileocecum (10.9%) and multiple gastrointestinal tract involvements (9.8%). The ratio of non-germinal center B cell (non-GCB) subtype to germinal center B cell (GCB) was 2:1. Among the cases, Ki-67 had a high level expression with a median positive rate >80%. Positive expression of Bcl-2 was detected in 52.1% cases (25/48). Evidence of Helicobacter pylori (Hp) infections was detected in 34.0% cases with stomach involvement. Of the patients, 75 were included in a follow-up study with a median time of 48 months (3-130 months). The complete remission(CR)rate was 66.7%(50/75),the partial remission (PR) rate was 22.7% (17/75) and the overall response rate was 89.4% (67/75). The 1-, 3- and 5- year survival rates of the patients were 85.3%, 66.2% and 60.5%, respectively. The incidence of secondary malignancy after chemotherapy was 2.7%. The multivariate analysis indicated that primary colic DLBCL or multiple involvements of gastrointestinal tract and low serum albumin level (<35 g/L) at diagnosis were independently associated with poor outcome. Patients who received chemotherapy combined with rituximab (43 cases) had a higher CR rate (79.1% vs 46.9%, P=0.008) and 5-year overall survival (77.5% vs 53.1%, P=0.0045) than those without rituximab (32 case).
CONCLUSIONPrimary gastrointestinal DLBCL was a highly invasive and heterogeneous malignancy. In our data, the proportion of non-GCB subtype was higher. Primary colic DLBCL and those with multiple involvements of gastrointestinal tract had poor survival. Low serum albumin at diagnosis indicated poor outcome. Rituximab treatment in addition to chemotherapy might help to improve the clinical outcome. Further prospective trails were needed to confirm our results.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Female ; Gastrointestinal Neoplasms ; diagnosis ; mortality ; pathology ; Humans ; Lymphoma, Large B-Cell, Diffuse ; diagnosis ; mortality ; pathology ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Rate
5.Prognostic factor analysis of 116 cases of primary gastrointestinal non-Hodgkin's lymphoma.
Xian-gan LIN ; Kai-hong HUANG ; De-rong XIE ; Tian-hao LIU
Journal of Southern Medical University 2008;28(2):243-245
OBJECTIVETo investigate the factors that affect the prognosis of primary gastrointestinal non-Hodgkin's lymphoma (PGI-NHL).
METHODSThe clinical data of 116 patients with pathologically confirmed PGI-NHL we treated from January 1993 to December 2003 were analyzed retrospectively. Kaplan-Meier survival analysis was used for analyzing the survival of the patients, and Log-rank test was performed to compare the survival rates in relation to different prognostic factors.
RESULTSThe 3-year and 5-year survival rates of the patients were 63.8% (74/116) and 48.2% (40/83), respectively. Univariate analysis revealed that the factors affecting the prognosis of the patients included the presence of B symptom, tumor size, clinical stage, pathological type, depth of invasion, and treatment methods. The patients with B symptom, tumor size no less than 10 cm, advanced clinical stage (stages III(E) and IV(E)), T-cell type, and invasion beyond the serosa who received only surgical management had poorer prognosis than those free of B symptom with tumor size <10 cm, early clinical stage (stages I(E) and II(E)), B-cell type, and submucosal or serosal invasion managed with chemotherapy alone or in combination with surgery. Multivariate analysis showed that B symptom, tumor size no less than 10 cm, advanced clinical stage (stages III(E) and IV(E)), T-cell type, invasion beyond the serosa, and surgery alone were independently associated with poor prognosis.
CONCLUSIONThe tumor size, clinical stage, pathological type, treatment methods are the independent factors affecting the prognosis of patients with PGI-NHL.
Adolescent ; Adult ; Aged ; Child ; Female ; Gastrointestinal Neoplasms ; diagnosis ; mortality ; pathology ; Humans ; Kaplan-Meier Estimate ; Lymphoma, Non-Hodgkin ; diagnosis ; mortality ; pathology ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Young Adult
6.The Prognosis of Liver Cirrhosis in Recent Years in Korea.
Young Sun KIM ; Soon Ho UM ; Ho Sang RYU ; Jung Bok LEE ; Jae Won LEE ; Dong Kyu PARK ; Yong Sik KIM ; Yoon Tae JIN ; Hoon Jai CHUN ; Hong Sik LEE ; Sang Woo LEE ; Jai Hyun CHOI ; Chang Duck KIM ; Jin Hai HYUN
Journal of Korean Medical Science 2003;18(6):833-841
The survival of a recent series of 823 cirrhosis patients who were followed up for a mean of 48 months was analyzed. Cirrhosis was ascribed to alcohol (26%), hepatitis virus B (58%), hepatitis virus C (11%) or both (2%), or was cryptogenic (3%). Features of decompensation were observed in 51% of the patients at entry, and newly developed in 44% of compensated patients within 5 yr. The 5-yr survival after decompensation was 25%. The leading causes of death were liver failure (53%), hepatocellular carcinoma (HCC, 23%), and variceal bleeding (10%). Early detection of HCC significantly improved the survival of cirrhosis patients. Biannual ultrasonography increased the detection rate of small HCC. Mortality of variceal hemorrhage was much lower in patients with Child-Pugh scores from 5 to 8 than in those with scores above 8 (5% vs. 52%). Endoscopic prophylaxis significantly decreased the incidence of first variceal hemorrhage, but the effect was insufficient to improve the rate of survival. Mortality of first spontaneous bacterial peritonitis was 18%. These data suggest that the mortality of major complications of liver cirrhosis has considerably decreased during the last two decades, while there was no remarkable improvement in long-term survival. More efficient management of etiologic factors would be required.
Adult
;
Aged
;
Carcinoma, Hepatocellular/etiology/physiopathology
;
Female
;
Gastrointestinal Hemorrhage
;
Human
;
Korea
;
Liver Cirrhosis/complications/*diagnosis/mortality/*physiopathology
;
Liver Neoplasms/etiology/pathology
;
Male
;
Middle Aged
;
Peritonitis
;
Prognosis
;
Retrospective Studies
;
*Survival Analysis
;
Survival Rate